Melissa Cooley, MD
Internal Medicine · Jefferson City, TNNPI 1851501670
Payments from drug & device makers
Across 133 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$719
- GSK$342
- Pfizer$284
- Welch Allyn$100
- Astellas Pharma US Inc$84
- Novartis$83
- plus $681 from 19 others
What the payments were for
- Food & beverage$2,293100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $719 |
| GSK | 18 | $342 |
| Pfizer | 24 | $284 |
| Welch Allyn | 2 | $100 |
| Astellas Pharma US Inc | 3 | $84 |
| Novartis | 6 | $83 |
| Heartflow, Inc. | 2 | $82 |
| Dexcom, Inc. | 4 | $74 |
| Lilly USA, LLC | 4 | $70 |
| Sequel Med Tech, LLC | 2 | $59 |
| Johnson & Johnson | 4 | $51 |
| Medtronic | 2 | $50 |
| AstraZeneca | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Boehringer Ingelheim | 2 | $32 |
| Merck | 2 | $25 |
| Abbott | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$110
How this compares
$2,293 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $93,831 |
| EliquisApixaban | 110 | $79,952 |
| MounjaroTirzepatide | 73 | $75,993 |
| OzempicSemaglutide | 47 | $50,352 |
| XareltoRivaroxaban | 36 | $28,928 |
| JanuviaSitagliptin Phosphate | 19 | $27,909 |
| MyrbetriqMirabegron | 20 | $21,903 |
| ElmironPentosan Polysulfate Sodium | 12 | $18,824 |
| LinzessLinaclotide | 17 | $15,652 |
| RybelsusSemaglutide | 13 | $14,123 |
| BrilintaTicagrelor | 30 | $13,879 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 55 | $12,397 |
| Spiriva RespimatTiotropium Bromide | 14 | $10,044 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,741 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $9,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Shingrix, Arexvy | $342 | $109,728162 claims |
| PfizerEliquis, Abrysvo | $284 | $86,438130 claims |
| Lilly USA, LLCMounjaro | $70 | $75,99373 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $719 | $68,61979 claims |
| Johnson & JohnsonXarelto | $51 | $28,92836 claims |
| MerckJanuvia | $25 | $27,90919 claims |
| AstraZenecaBrilinta, Breztri Aerosphere, Symbicort | $49 | $26,91259 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $21,90320 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $32 | $17,30526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Jefferson City
- John KirbyJefferson City$1.2M
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.